A client who is experiencing vasomotor symptoms related to menopause receives a new prescription for estrogen replacement. Which client condition should the nurse report the healthcare provider prior to administering the first dose of the medication?

A) Undergo annual eye examinations:
While methotrexate and adalimumab can both have potential ocular side effects, such as blurred vision or eye pain, the need for annual eye examinations is more commonly associated with methotrexate therapy. Methotrexate can cause ocular toxicity, including retinopathy and optic neuropathy, which necessitates regular monitoring by an ophthalmologist. However, adalimumab is not typically associated with annual eye examinations, so this instruction is not directly relevant to the addition of adalimumab to the client’s regimen.

B) Have a chest x-ray prior to your first dose:
A chest x-ray is not routinely required before initiating adalimumab therapy. While screening for tuberculosis (TB) may be necessary in clients starting adalimumab due to its immunosuppressive effects, a chest x-ray is not always indicated for this purpose. Instead, TB screening usually involves a thorough history, physical examination, and possibly tuberculin skin testing or interferon-gamma release assays. Therefore, this instruction is not specifically related to the addition of adalimumab to the client’s treatment regimen.

C) Avoid crowds and people who are sick:
Adalimumab is a biologic disease-modifying antirheumatic drug (DMARD) that suppresses the immune system’s inflammatory response by targeting tumor necrosis factor-alpha (TNF-alpha). As a result, clients taking adalimumab are at increased risk of infections, including bacterial, viral, and fungal infections. Therefore, instructing the client to avoid crowds and individuals who are sick helps reduce the risk of exposure to infectious pathogens and minimize the likelihood of developing infections while on adalimumab therapy.

D) Obtain routine vaccinations as scheduled:
While maintaining up-to-date vaccinations is important for overall health and immunity, clients receiving biologic DMARDs like adalimumab may have a reduced response to vaccines due to immunosuppression. Therefore, it is generally recommended to administer necessary vaccinations before starting adalimumab therapy whenever possible. However, the decision to administer vaccines should be individualized, and certain live vaccines may be contraindicated while receiving adalimumab. Nonetheless, this instruction is not directly related to the addition of adalimumab to the client’s medication regimen.

A) When using the discus, have the client breathe out rapidly into the mouthpiece: This instruction is incorrect because with dry powder inhalers (DPIs) like the fluticasone propionate and salmeterol discus, clients should exhale slowly and completely before inhaling the medication. Breathing out rapidly may cause the medication to be dispersed ineffectively, reducing its therapeutic benefit. By exhaling slowly, clients ensure better delivery of the medication to their lungs, maximizing its effectiveness in controlling asthma symptoms.
B) Explain that the client should not use the discus more than twice daily: This is the correct answer. Fluticasone propionate and salmeterol combination inhalers are typically used on a scheduled basis to maintain asthma control. Overuse of these medications can lead to increased risk of side effects, such as oral thrush or hoarseness from the steroid component (fluticasone propionate), or increased heart rate from the long-acting beta agonist (salmeterol). Moreover, exceeding the prescribed dose may not provide additional benefits in controlling asthma symptoms and can indicate inadequate control, necessitating a review of the treatment plan by the healthcare provider.
C) Offer the discus to the client for use during an acute asthma attack: Using a combination inhaler during an acute asthma attack is not appropriate. During acute exacerbations, clients should use short-acting bronchodilators (e.g., albuterol) for quick relief of symptoms. Combination inhalers like fluticasone propionate and salmeterol are intended for long-term maintenance therapy to prevent asthma symptoms, not for acute symptom relief.
D) Clients using the discus may experience decreased blood pressure: This statement is incorrect. Fluticasone propionate and salmeterol combination inhalers are not known to cause decreased blood pressure as a side effect. However, salmeterol, being a long-acting beta agonist, can potentially cause an increase in heart rate, especially when used excessively, but this is not related to blood pressure changes. It's essential to focus on the appropriate use and dosing schedule of the medication to achieve optimal asthma control and minimize adverse effects.